Ethosuximide NDC 69452-152

NDC codes

FDA NDC Directory

Product NDC (as listed)69452-152Labeler and product segments. Claims need a package NDC.

Product NDC at billing width69452-0152Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
69452-152-20	69452015220	100 CAPSULE, LIQUID FILLED in 1 BOTTLE, PLASTIC (69452-152-20)Marketed from Oct 21, 2016

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ethosuximide
Generic name (nonproprietary): ethosuximide
Active ingredients: Ethosuximide — 250 mg/1
Dosage form: Capsule, Liquid filled
Route: Oral
Labeler: Bionpharma Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 040430
Marketing start: Oct 21, 2016
Listing expires: Dec 31, 2026
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 69452-152_0d82d9c4-814d-ed9b-e063-6294a90a6522SPL ID 0d82d9c4-814d-ed9b-e063-6294a90a6522SPL set ID efb047e8-0020-4504-97fa-6aa1af3af05eRxCUI 197682UNII 5SEH9X1D1DUPC 0369452152201
Pharmacologic class: Anti-epileptic Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N469452015220 followed by a unit qualifier and the quantity

Package 69452-0152-20. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 27, 2023.

Indications (excerpt from the label)

INDICATIONS AND USAGE Ethosuximide capsules are indicated for the control of absence (petit mal) epilepsy.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 040430

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 040430
Product	Strength	Form · route	Labeler	Product NDC
Ethosuximide	Ethosuximide 250 mg/1	Capsule, Liquid filledOral	Bryant Ranch Prepack	63629-8005